Fig. 5: dl5-29 vaccination is immunogenic and protective in naïve animals challenged on the skin. | npj Vaccines

Fig. 5: dl5-29 vaccination is immunogenic and protective in naïve animals challenged on the skin.

From: Model of vaccine efficacy against HSV-2 superinfection of HSV-1 seropositive mice demonstrates protection by antibodies mediating cellular cytotoxicity

Fig. 5

Female C57BL6 mice were vaccinated with 5 × 106 pfu/mouse of dl5-29 3 weeks apart. One week following boost vaccination, serum was collected and assessed for a total HSV-2-specific IgG by ELISA; b neutralizing titer; and c FcγRIV activation (mFcγRIV ADCC Reporter Bioassay, Promega). Three weeks following boost vaccination, mice vaccinated with dl5-29 or rgD-2/alum-MPL were challenged on the skin with a 1 × LD90 of HSV-2 SD90. Mice were monitored over 14 days for signs of disease and percentage survival is shown in d. Survival was compared by Gehan–Breslow–Wilcoxon test. The asterisks (****) indicate p < 0.0001, **p < 0.01, *p < 0.05 by Student’s t-test (a–c) or Gehan–Breslow–Wilcoxon test (d). Data are shown as mean + SEM. n = 10 for dl5-29 and VD60; n = 5 for rgD-2/alum-MPL.

Back to article page